Meeting
2022 ASCO Genitourinary Cancers Symposium
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.
Authors
A. Oliver Sartor
School of Medicine, Tulane Medical School, New Orleans, LA
A. Oliver Sartor , Scott T. Tagawa , Fred Saad , Johann S. De Bono , Felix Y Feng , Karim Fizazi , Olga V. Sakharova , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04720157
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS210)
DOI
10.1200/JCO.2022.40.6_suppl.TPS210
Abstract #
TPS210
Poster Bd #
Q9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
First Author: Scott T. Tagawa
Poster
2024 ASCO Genitourinary Cancers Symposium
CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Gliceida Galarza Fortuna
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins